Ochre Bio, Boehringer ink $1bn deal to tackle chronic liver disease
Pharmaceutical Technology - 23-Apr-2024AI and genomics to drive new regenerative therapies, with $35m upfront to Ochre Bio
Ochre Bio
Biotechnology company developing RNA medicines for liver diseases
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases using a combination of genomics, machine learning and experimental biology on live human organs. The company uncovers new biological pathways by using advances in 'deep phenotyping', and then studies medicines in human livers.
Ochre Bio brings an extra dimension to drug development data, called deep phenotyping, to study disease and gene systems at a tissue level.
Ochre Bio Executive Team
• Jack Castle, Associate Director, Product Management
• Jack O’ Meara, Co-founder and CEO
• Quin Wills, Co-Founder and CSO
Ochre Bio Board Members
• Alasdair Thong
• Troy Dale
Visit website: https://www.ochre-bio.com/
Details last updated 05-Dec-2021
Ochre Bio News
Discarded donor livers to be maintained in Liver ICU in USA by Ochre Bio to discover new therapies
Business Wire - 11-May-2022Liver ICU main aim-Improve liver transplant processes and discover therapies for liver diseases
Apollo Health Ventures raised $180M fund to invest in longevity innovations
Endpoints News - 01-Dec-2021Invests in early stage companies that target root causes of age-related diseases
Ochre Bio secures $9.6M funding for development of RNA therapies
Business Wire - 16-Jun-2021Convergence of genomic technologies and machine learning digitizes liver biology
Mentioned in this Resource
